We are live on ! Find out more
PCVX icon

Vaxcyte

75 hedge funds and large institutions have $971M invested in Vaxcyte in 2021 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 35 increasing their positions, 16 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

119% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 16

12% more capital invested

Capital invested by funds: $868M → $971M (+$103M)

1% more funds holding

Funds holding: 7475 (+1)

9% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 11

1.64% less ownership

Funds ownership: 85.76%84.12% (-1.6%)

20% less funds holding in top 10

Funds holding in top 10: 54 (-1)

Holders
75
Holders Change
+1
Holders Change %
+1.35%
% of All Funds
1.31%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.07%
New
12
Increased
35
Reduced
16
Closed
11
Calls
$254K
Puts
Net Calls
+$254K
Net Calls Change
-$106K

PCVX Hedge Fund Activity: Q2 2021 in Review

75 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Vaxcyte (PCVX) for Q2 2021, worth a combined $971M — up 12% from $868M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new PCVX positions and 11 closed out — a net gain of 1 holder — while 35 added to existing stakes and 16 trimmed.

The largest buyer was OrbiMed, adding an estimated $6.07M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $16.8M sold.

  • 75 institutional investors held Vaxcyte (PCVX) as of Q2 2021, up from 74 in Q1 2021.
  • Funds reported $971M of Vaxcyte stock for Q2 2021, up 12% quarter-over-quarter.
  • 12 funds opened new Vaxcyte positions in Q2 2021 and 11 closed out, a net change of +1 holder.
  • The largest Vaxcyte buyer in Q2 2021 was OrbiMed, an estimated $6.07M added.
  • The largest Vaxcyte seller in Q2 2021 was Perceptive Advisors, an estimated $16.8M sold.

Based on aggregated 13F filings for Q2 2021.